Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-(+)-2-[4-(fluorobenzyloxy-benzylamino)propionamide] is a synthetic small molecule belonging to the class of alanine derivatives. It has the molecular formula C17H17FN2O2 and a molecular weight of approximately 300.33 g/mol. The compound is primarily referenced in chemical and pharmacological databases as an experimental or research molecule, with no approved medical indications or known clinical development for any disease as of June 2025. Its mechanism of action, biological targets, and therapeutic potential have not been established in publicly available literature or drug development pipelines[1][2][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-(+)-2-[4-(fluorobenzyloxy-benzylamino)propionamide].